Taking aim at Xolair, Celldex offers a positive early readout for their rival drug — but researchers have a lot of work remaining
The researchers at Celldex are flagging some positive data from a small early stage trial for their drug barzolvolimab in patients with moderate to severe chronic spontaneous urticaria not responding to antihistamines.
The key figure: The drug triggered a 57.1% complete response in the low 1.5 mg/kg dose arm of the trial after 12 weeks with the higher 3.0 mg/kg scoring 44% after 8 weeks, which reflects a single dose for an ongoing treatment arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.